99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of Abiomed, Inc. Investors. Click "Join this Class Action" above.

Attorneys

Abiomed, Inc.

Join Class Action »

Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Abiomed, Inc. (NASDAQ: ABMD) from January 31, 2019 through July 31, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Abiomed investors under the federal securities laws.

If you bought Abiomed securities between January 31, 2019 and July 31, 2019, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Abiomed, Inc. – ABMD

New York, N.Y., August 7, 2019. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Abiomed, Inc. (NASDAQ: ABMD) from January 31, 2019 through July 31, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Abiomed investors under the federal securities laws.

To join the Abiomed class action, go to http://zhanginvestorlaw.com/cases/abiomed-inc/ or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) ABIOMED’s revenue growth was in decline; (2) ABIOMED did not have a sufficient plan in place to stem its declining revenue growth; (3) ABIOMED was unlikely to restore its revenue growth over the next several fiscal quarters; (4) consequently, ABIOMED was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company’s prior projections and market expectations; and (5) as a result, ABIOMED’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 7, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/abiomed-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.
——————————-